You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ocrevus

Showing 1 - 25 of 38
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing-remitting Multiple Sclerosis Trial (CT-P53, US-Ocrevus, EU-Ocrevus)

Not yet recruiting
  • Relapsing-remitting Multiple Sclerosis
  • CT-P53
  • +2 more
  • (no location specified)
Jun 7, 2023

Mechanistic Study of Ocrevus

Recruiting
  • Multiple Sclerosis
  • Ann Arbor, Michigan
    University of Michigan
Jul 27, 2022

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Ocrevus
  • West Orange, New Jersey
    Kessler Foundation
Oct 12, 2022

Upper Extremity Function in Multiple Sclerosis Advanced

Active, not recruiting
  • Multiple Sclerosis
  • +7 more
  • Tampa, Florida
    Carol and Frank Morsani Center for Advanced Healthcare
Nov 2, 2022

Multiple Sclerosis Trial (Ocrelizumab Injection [Ocrevus])

Not yet recruiting
  • Multiple Sclerosis
  • Ocrelizumab Injection [Ocrevus]
  • (no location specified)
Aug 22, 2023

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Ocrelizumab Effects on the Metabolome in MS

Active, not recruiting
  • Multiple Sclerosis
  • Baltimore, Maryland
    Johns Hopkins University
Jan 30, 2023

Relapsing Multiple Sclerosis Trial in Atlanta (Ocrelizumab, Platform)

Recruiting
  • Relapsing Multiple Sclerosis
  • Atlanta, Georgia
  • +1 more
Sep 14, 2021

The 'Wearing Off' Effect of DMT

Recruiting
  • Multiple Sclerosis
  • ocrelizumab
  • +2 more
  • Basel, Switzerland
    Novartis Investigative Site
Jan 24, 2023

Secondary-progressive Multiple Sclerosis Trial in Buffalo (Mayzent, Ocrevus)

Recruiting
  • Secondary-progressive Multiple Sclerosis
  • Buffalo, New York
    University at Buffalo, Buffalo General Hospital
Oct 10, 2022

Symptom Burden in Patients Treated With Ocrelizumab for Multiple

Active, not recruiting
  • Multiple Sclerosis
  • Wellesley, Massachusetts
  • +1 more
Oct 14, 2022

Disease Processes in Multiple Sclerosis

Active, not recruiting
  • Multiple Sclerosis
  • All patients in the study will be treated with ocrelizumab
  • Portland, Oregon
  • +1 more
Sep 29, 2022

Ocrelizumab in Breastmilk

Active, not recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • San Francisco, California
    University of California, San Francisco
Mar 21, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in Amsterdam (Ocrelizumab)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Amsterdam, Noord-Holland, Netherlands
    Amsterdam UMC, location VU
Apr 21, 2022

Cladribine Therapy After Anti CD20 Therapy

Active, not recruiting
  • Multiple Sclerosis
  • Cladribine Oral Tablet
  • +2 more
  • Lugano, Ticino, Switzerland
    Neurocenter of Southern Switzerland, Ospedale Regionale di Lugan
Mar 22, 2022

Relapsing Multiple Sclerosis, Clinically Isolated Syndrome Trial in San Francisco (Ocrelizumab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Clinically Isolated Syndrome
  • San Francisco, California
    University of California San Francisco
Apr 28, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in Iran, Islamic Republic of (Ocrelizumab (CinnaGen, Iran), Ocrelizumab (Roche,

Active, not recruiting
  • Multiple Sclerosis
  • Relapsing-Remitting
  • Ocrelizumab (CinnaGen, Iran)
  • Ocrelizumab (Roche, Switzerland)
  • Rasht, Guilan, Iran, Islamic Republic of
  • +14 more
Aug 31, 2021

Multiple Sclerosis Trial in United States (Ocrelizumab, Placebo for Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • New Haven, Connecticut
  • +9 more
Jan 17, 2023

Multiple Sclerosis Trial in Aurora (Ocrelizumab, Rituximab)

Completed
Has Results
  • Multiple Sclerosis
  • Aurora, Colorado
    University of Colorado Hospital
Jul 1, 2021

Relapsing Remitting Multiple Sclerosis Trial in Norway (Rituximab, Ocrelizumab)

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Bergen, Norway
  • +10 more
Mar 18, 2022

Oncology Patients Receiving Chemo Trial in United States (Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as

Completed
Has Results
  • Oncology Patients Receiving Chemotherapy
  • Cetirizine HCl 10 mg/mL
  • +2 more
  • Napa, California
  • +6 more
Apr 25, 2022

Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • +2 more
  • Glostrup, Copenhagen, Denmark
  • +11 more
May 3, 2022

Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United

Recruiting
  • Relapsing Multiple Sclerosis
  • +2 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • Best Available Therapy (BAT)
  • Palo Alto, California
  • +20 more
Jan 25, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in United Kingdom, United States (Early Highly Effective Therapies Group,

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Early Highly Effective Therapies Group
  • Escalation Therapies Group
  • Aurora, Colorado
  • +30 more
Jul 22, 2022

Multiple Sclerosis, Clinically Isolated Syndrome Trial in Worldwide (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • San Francisco, California
  • +5 more
Aug 2, 2022